Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis a review of cost-effectiveness
The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa
CADTH
March 26, 2019, 2019
|
Edition: | Version: 1.0 |
Series: | CADTH rapid response report
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America |
---|---|
Physical Description: | 1 PDF file (18 pages) illustration |